Harrow Health, Inc. (Harrow Health), an ophthalmic-focused healthcare company, closed its underwritten registered public offering of $20 million aggregate principal amount of 8.625% senior notes due 2026 (the Notes), which includes the full exercise of the over-allotment option of $2.5 million aggregate principal amount granted to the underwriters. The Notes will be treated as a single series with Harrow Health’s outstanding 8.625% senior notes due 2026 and will trade interchangeably with the existing notes. The offering resulted in net proceeds of approximately $19.6 million after deducting underwriting discounts and commission, but before expenses.
Waller acted as legal counsel to Harrow Health.
For more information, see press release: here.
Whether a current or prospective client, we are here to help your business thrive. Please send us a message and we will respond to your needs as soon as possible.Send us a message